Soligenix initiates Phase 2 trial of SGX945 (dusquetide) for Behçet's Disease treatment, aiming to address unmet medical needs with a focus on severe ulcers. The open-label study will enroll 25 patients with mild to moderate Behçet's Disease, evaluating SGX945's efficacy in lesion clearance and quality of life. Dusquetide, an innate defense regulator, has shown promise in previous studies for oral mucositis and may offer significant relief for Behçet's Disease patients.